Company news

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A (SSE:688513) news

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement…

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A (SSE:688513) news

Press releases & updates

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Closure of Certain Special Accounts for Raised Funds

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Progress of Phase I Clinical Trials for EP-0226 Tablets

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Resolutions of the 16th Meeting of the 4th Board of Directors

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Implementation Results of Share Repurchase

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Progress in Repurchasing Shares

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for HP-002 Tablets and Completion of First Subject Enrollment and Dosing

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on the Voluntary Disclosure of Obtaining Drug Registration Certificate for Remimazolam Besylate for Injection

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading

"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Resolutions of the 14th Meeting of the 4th Board of Directors

"Chengdu Easton Bio Pharmaceuticals Co.,Ltd"Announcement on Progress in Repurchasing Shares

Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2024 Restricted Stock Incentive Plan

Indicative Announcement on Tax-Related Matters of a Subsidiary

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on the Achievement of Performance Assessment Targets for the 2nd Lock-up Period of the 2024 Employee Stock Ownership Plan and the Expiry of the Lock-up Period

Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive Plan

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Announcement on Canceling Some Restricted Stocks in the 2024 Restricted Stock Incentive Plan

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Voluntary Disclosure of Obtaining a Drug Registration Certificate for Vitamin K1 Injection

Announcement on Serious Abnormal Fluctuations in Stock Trading

Announcement on Cancellation of Some Special Accounts for Raised Funds

Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for the Class 2 Modified New Drug - Amhydrocodone Paracetamol Extended-Release Tablets

Announcement on Application for Comprehensive Credit Line and Provision of Mutual Guarantee by the Company and Its Subsidiary in 2026

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Midazolam Hydrochloride Oral Solution

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry

Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection

Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0226 Tablets

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Class 2 Modified New Drugs - Chloral Hydrate/Syrup

Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I/II Clinical Trial of HP-001 Capsules Combined with Dexamethasone

Announcement on Voluntary Disclosure of U.S. FDA Approval for Methylene Blue Injection

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Brexpiprazole Tablets

Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site Inspection

Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for YLSH003 for Injection and Completion of the 1st Subject Enrollment

Announcement on Progress in Completion of Capital Increase to Joint-stock Company and Related Party Transactions

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement

Report for Q3 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Voluntary Disclosure of Iguratimod Tablets Obtaining Drug Registration Certificate

Announcement on New Recognized Core Technical Personnel

Announcement on Progress in Capital Increase in Joint-stock Company and Related Party Transactions

Announcement on Election of Employee Representative Directors for the 4th Board of Directors